Open AccessBronchodilator activity of Mikania glomerata Sprengel on human bronchi and guinea‐pig trachea
Author(s) -
Moura R. Soares,
Costa S. S.,
Jansen J. M.,
Silva C. A.,
Lopes C. S.,
BernardoFilho M.,
Silva V. Nascimento,
Criddle D. N.,
Portela B. Nunes,
Rubenich L. M. S.,
Araújo R. Gagliardi,
Carvalho L. C. R. M.
Publication year - 2002
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1211/0022357021778277
Subject(s) - guinea pig , histamine , ic50 , dichloromethane , bronchoconstriction , bronchodilatation , vasodilation , pharmacology , chemistry , medicine , bronchodilator , chromatography , anesthesia , airway , biochemistry , in vitro , asthma , solvent
The effects of aqueous extracts and hydro‐alcoholic extract (HAE), and of a dichloromethane fraction (MG1) obtained from the HAE of Mikania glomerata leaves on isolated respiratory and vascularsmooth muscle have been investigated. Aqueousextracts and HAE induced a significant inhibition on the histamine contractions on the isolated guinea‐pig trachea. HAE extract induced a concentration‐dependent relaxation on guinea‐pig trachea pre‐contracted with histamine (IC50 0.34 (0.29‐0.39) mg mL −1 ), acetylcholine (IC50 0.72 (0.67‐0.77) mg ml −1 ) or K + (IC50 1.41 (1.18‐1.64) mg mL −1 ) and on isolated human bronchi precontracted with K + (IC50 0.34 (0.26‐0.42) mg mL −1 ). The dichloromethane fraction induced a concentration dependent relaxation in guinea‐pig trachea precontracted with K + (IC50 0.017 (0.012‐0.022) mg mL −1 ). The dichloromethane fraction had also a small vasodilator effect on the isolated mesenteric vascular bed and on the isolated rat aorta, and a significant reduction of the oedema induced by subplantar injections of Bothrops jararaca venom in mice. When tested on plasmid DNA, MG1 did not damage the DNA. Chromatographic analysis showed the presence of 11.4% w/w coumarin in MG1. The results supported the indication of M. glomerata products for the treatment of respiratory diseases where bronchoconstriction is present.